Bristol-Myers Squibb (BMY) EBITDA Margin: History & Chart

Bristol-Myers Squibb Company(BMY)

Drug Manufacturers - General · Princeton, NJ

$64.04+0.30 (+0.48%)

Delayed quote: Sep 16, 2026, 1:55 PM EDT

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

Princeton, NJ

32,500 employees

www.bms.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Christopher Boerner

View full financials

BMY EBITDA Margin Metrics

EBITDA MARGIN

36.80%

EBITDA MARGIN AVG TTM

35.36%

EBITDA MARGIN AVG 3Y

37.65%

EBITDA MARGIN AVG 5Y

38.92%

EBITDA MARGIN AVG 10Y

35.13%

EBITDA MARGIN AVG 15Y

30.79%

EBITDA MARGIN AVG 20Y

29.60%

CURRENT VS TTM AVG

+4.08%

CURRENT VS 3Y AVG

-2.25%

CURRENT VS 5Y AVG

-5.45%

CURRENT VS 10Y AVG

+4.77%

CURRENT VS 15Y AVG

+19.51%

CURRENT VS 20Y AVG

+24.33%

NAME	MARKET CAP	EBITDA MARGIN	TTM	3Y	5Y
Bristol-Myers Squibb Company (BMY)	$130.80B	36.80%	35.36%	37.65%	38.92%
Vertex Pharmaceuticals Incorporated (VRTX)vs ›	$130.91B	41.14%	20.45%	32.86%	36.27%
Intuitive Surgical, Inc. (ISRG)vs ›	$135.24B	35.99%	34.83%	32.83%	33.22%
Medtronic plc (MDT)vs ›	$119.50B	25.92%	26.11%	25.62%	25.51%
CVS Health Corp. (CVS)vs ›	$119.01B	3.73%	3.63%	4.02%	4.83%
Danaher Corporation (DHR)vs ›	$147.44B	30.87%	31.21%	32.47%	31.98%
Stryker Corporation (SYK)vs ›	$110.41B	24.22%	25.63%	25.70%	26.23%
Pfizer Inc. (PFE)vs ›	$156.91B	32.51%	34.72%	32.84%	32.73%
McKesson Corporation (MCK)vs ›	$104.44B	1.78%	1.58%	1.64%	1.66%
Sanofi (SNY)vs ›	$102.81B	32.70%	28.59%	29.32%	32.36%

NAME

MARKET CAP

EBITDA MARGIN

TTM

Bristol-Myers Squibb Company (BMY)

$130.80B

36.80%

35.36%

37.65%

38.92%

Vertex Pharmaceuticals Incorporated (VRTX)vs ›

$130.91B

41.14%

20.45%

32.86%

36.27%

Intuitive Surgical, Inc. (ISRG)vs ›

$135.24B

35.99%

34.83%

32.83%

33.22%

Medtronic plc (MDT)vs ›

$119.50B

25.92%

26.11%

25.62%

25.51%

CVS Health Corp. (CVS)vs ›

$119.01B

3.73%

3.63%

4.02%

4.83%

Danaher Corporation (DHR)vs ›

$147.44B

30.87%

31.21%

32.47%

31.98%

Stryker Corporation (SYK)vs ›

$110.41B

24.22%

25.63%

25.70%

26.23%

Pfizer Inc. (PFE)vs ›

$156.91B

32.51%

34.72%

32.84%

32.73%

McKesson Corporation (MCK)vs ›

$104.44B

1.78%

1.58%

1.64%

1.66%

Sanofi (SNY)vs ›

$102.81B

32.70%

28.59%

29.32%

32.36%

EBITDA Margin FAQ

What is the EBITDA margin for Bristol-Myers Squibb Company (BMY)?

The EBITDA margin for BMY stock is 36.80%.

Is Bristol-Myers Squibb Company's EBITDA margin high or low?

The EBITDA margin of 36.80% is in line with its 5-year average of 38.92%, around the middle of its 5-year range (30.31%–45.46%).

What is the TTM average EBITDA margin for Bristol-Myers Squibb Company (BMY)?

The TTM average EBITDA margin for BMY stock is 35.36%.

What is the 3Y average EBITDA margin for Bristol-Myers Squibb Company (BMY)?

The 3Y average EBITDA margin for BMY stock is 37.65%.

What is the 5Y average EBITDA margin for Bristol-Myers Squibb Company (BMY)?

The 5Y average EBITDA margin for BMY stock is 38.92%.

What is the 10Y average EBITDA margin for Bristol-Myers Squibb Company (BMY)?

The 10Y average EBITDA margin for BMY stock is 35.13%.

What is the 15Y average EBITDA margin for Bristol-Myers Squibb Company (BMY)?

The 15Y average EBITDA margin for BMY stock is 30.79%.

What is the 20Y average EBITDA margin for Bristol-Myers Squibb Company (BMY)?

The 20Y average EBITDA margin for BMY stock is 29.60%.

DATE	EBITDA MARGIN
2026-06-30	34.96%
2026-03-31	34.46%
2025-12-31	30.31%
2025-09-30	38.05%
2025-06-30	39.00%
2025-03-31	40.26%
2024-12-31	35.74%
2024-09-30	41.04%
2024-06-30	42.46%
2024-03-31	34.28%
2023-12-31	38.48%
2023-09-30	41.39%
2023-06-30	38.97%
2023-03-31	43.06%
2022-12-31	37.13%
2022-09-30	42.95%
2022-06-30	44.35%
2022-03-31	45.46%
2021-12-31	40.16%
2021-09-30	38.36%
2021-06-30	36.49%
2021-03-31	43.94%
2020-12-31	30.91%
2020-09-30	38.15%
2020-06-30	34.52%
2020-03-31	31.58%
2019-12-31	24.38%
2019-09-30	32.85%
2019-06-30	34.86%
2019-03-31	32.99%
2018-12-31	29.50%
2018-09-30	32.37%
2018-06-30	12.55%
2018-03-31	29.58%
2017-12-31	22.50%
2017-09-30	23.83%
2017-06-30	33.30%
2017-03-31	36.68%
2016-12-31	21.34%
2016-09-30	29.26%
2016-06-30	25.17%
2016-03-31	26.83%
2015-12-31	-1.28%
2015-09-30	17.72%
2015-06-30	5.14%
2015-03-31	30.34%
2014-12-31	2.40%
2014-09-30	20.79%
2014-06-30	10.65%
2014-03-31	22.30%
2013-12-31	23.49%
2013-09-30	23.76%
2013-06-30	20.18%
2013-03-31	22.66%
2012-12-31	17.18%
2012-09-30	20.13%
2012-06-30	26.02%
2012-03-31	37.75%
2011-12-31	32.73%
2011-09-30	34.18%
2011-06-30	35.76%
2011-03-31	35.54%
2010-12-31	26.08%
2010-09-30	36.24%
2010-06-30	35.72%
2010-03-31	34.66%
2009-12-31	33.78%
2009-09-30	29.58%
2009-06-30	28.94%
2009-03-31	23.19%
2008-12-31	18.99%
2008-09-30	26.61%
2008-06-30	28.60%
2008-03-31	25.81%
2007-12-31	17.82%
2007-09-30	21.60%
2007-06-30	21.51%
2007-03-31	22.36%
2006-12-31	10.68%
2006-09-30	16.56%
2006-06-30	26.01%
2006-03-31	24.44%
2005-12-31	21.42%
2005-09-30	25.11%
2005-06-30	27.69%
2005-03-31	27.67%
2004-12-31	37.10%
2004-09-30	25.98%
2004-06-30	25.03%
2004-03-31	26.02%
2003-12-31	24.28%
2003-09-30	29.72%
2003-06-30	28.44%
2003-03-31	27.74%
2002-12-31	22.28%
2002-09-30	27.84%

DATE

EBITDA MARGIN

2026-06-30

34.96%

2026-03-31

34.46%

2025-12-31

30.31%

2025-09-30

38.05%

2025-06-30

39.00%

2025-03-31

40.26%

2024-12-31

35.74%

2024-09-30

41.04%

2024-06-30

42.46%

2024-03-31

34.28%

2023-12-31

38.48%

2023-09-30

41.39%

2023-06-30

38.97%

2023-03-31

43.06%

2022-12-31

37.13%

2022-09-30

42.95%

2022-06-30

44.35%

2022-03-31

45.46%

2021-12-31

40.16%

2021-09-30

38.36%

2021-06-30

36.49%

2021-03-31

43.94%

2020-12-31

30.91%

2020-09-30

38.15%

2020-06-30

34.52%

2020-03-31

31.58%

2019-12-31

24.38%

2019-09-30

32.85%

2019-06-30

34.86%

2019-03-31

32.99%

2018-12-31

29.50%

2018-09-30

32.37%

2018-06-30

12.55%

2018-03-31

29.58%

2017-12-31

22.50%

2017-09-30

23.83%

2017-06-30

33.30%

2017-03-31

36.68%

2016-12-31

21.34%

2016-09-30

29.26%

2016-06-30

25.17%

2016-03-31

26.83%

2015-12-31

-1.28%

2015-09-30

17.72%

2015-06-30

5.14%

2015-03-31

30.34%

2014-12-31

2.40%

2014-09-30

20.79%

2014-06-30

10.65%

2014-03-31

22.30%

2013-12-31

23.49%

2013-09-30

23.76%

2013-06-30

20.18%

2013-03-31

22.66%

2012-12-31

17.18%

2012-09-30

20.13%

2012-06-30

26.02%

2012-03-31

37.75%

2011-12-31

32.73%

2011-09-30

34.18%

2011-06-30

35.76%

2011-03-31

35.54%

2010-12-31

26.08%

2010-09-30

36.24%

2010-06-30

35.72%

2010-03-31

34.66%

2009-12-31

33.78%

2009-09-30

29.58%

2009-06-30

28.94%

2009-03-31

23.19%

2008-12-31

18.99%

2008-09-30

26.61%

2008-06-30

28.60%

2008-03-31

25.81%

2007-12-31

17.82%

2007-09-30

21.60%

2007-06-30

21.51%

2007-03-31

22.36%

2006-12-31

10.68%

2006-09-30

16.56%

2006-06-30

26.01%

2006-03-31

24.44%

2005-12-31

21.42%

2005-09-30

25.11%

2005-06-30

27.69%

2005-03-31

27.67%

2004-12-31

37.10%

2004-09-30

25.98%

2004-06-30

25.03%

2004-03-31

26.02%

2003-12-31

24.28%

2003-09-30

29.72%

2003-06-30

28.44%

2003-03-31

27.74%

2002-12-31

22.28%

2002-09-30

27.84%

EBITDA Margin: 36.80%

BMY EBITDA Margin

BMY Average EBITDA Margin Chart

BMY Current vs Average EBITDA Margin Chart

BMY EBITDA Margin Metrics

BMY Competitors' EBITDA Margin

Margin Comparison

EBITDA Margin Formula & Definition

EBITDA Margin FAQ

BMY EBITDA Margin History

Related Metrics